Oak Hill Bio and Chiesi Group Announce First Patient Enrolled in the Resumed Phase 2b Clinical Study Evaluating OHB-607 for the Prevention of Bronchopulmonary Dysplasia, the Most Common Cause of Chronic Lung Disease in Premature Infants
Business Wire
PARMA, Italy--(BUSINESS WIRE)--Oak Hill Bio, a clinical-stage neonatology and rare disease therapeutics company, and Chiesi, an..